These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25248679)

  • 21. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of orexin receptor antagonism on human sleep architecture: A systematic review.
    Clark JW; Brian ML; Drummond SPA; Hoyer D; Jacobson LH
    Sleep Med Rev; 2020 Oct; 53():101332. PubMed ID: 32505969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach.
    Heidmann B; Gatfield J; Roch C; Treiber A; Tortoioli S; Brotschi C; Williams JT; Bolli MH; Abele S; Sifferlen T; Jenck F; Boss C
    ChemMedChem; 2016 Oct; 11(19):2132-2146. PubMed ID: 27390287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics.
    Janto K; Prichard JR; Pusalavidyasagar S
    J Clin Sleep Med; 2018 Aug; 14(8):1399-1408. PubMed ID: 30092886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists.
    Yoshida Y; Terauchi T; Naoe Y; Kazuta Y; Ozaki F; Beuckmann CT; Nakagawa M; Suzuki M; Kushida I; Takenaka O; Ueno T; Yonaga M
    Bioorg Med Chem; 2014 Nov; 22(21):6071-88. PubMed ID: 25267004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists.
    Skudlarek JW; DiMarco CN; Babaoglu K; Roecker AJ; Bruno JG; Pausch MA; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Wuelfing WP; Garson SL; Fox SV; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Kuduk SD; Coleman PJ
    Bioorg Med Chem Lett; 2017 Mar; 27(6):1364-1370. PubMed ID: 28216403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
    Cox CD; Breslin MJ; Whitman DB; Schreier JD; McGaughey GB; Bogusky MJ; Roecker AJ; Mercer SP; Bednar RA; Lemaire W; Bruno JG; Reiss DR; Harrell CM; Murphy KL; Garson SL; Doran SM; Prueksaritanont T; Anderson WB; Tang C; Roller S; Cabalu TD; Cui D; Hartman GD; Young SD; Koblan KS; Winrow CJ; Renger JJ; Coleman PJ
    J Med Chem; 2010 Jul; 53(14):5320-32. PubMed ID: 20565075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats.
    Brotschi C; Bolli MH; Gatfield J; Roch C; Sifferlen T; Treiber A; Williams JT; Boss C
    RSC Med Chem; 2024 Jan; 15(1):344-354. PubMed ID: 38283232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orexin receptor antagonists: medicinal chemistry and therapeutic potential.
    Roecker AJ; Coleman PJ
    Curr Top Med Chem; 2008; 8(11):977-87. PubMed ID: 18673167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.
    Sifferlen T; Boller A; Chardonneau A; Cottreel E; Gatfield J; Treiber A; Roch C; Jenck F; Aissaoui H; Williams JT; Brotschi C; Heidmann B; Siegrist R; Boss C
    Bioorg Med Chem Lett; 2015 May; 25(9):1884-91. PubMed ID: 25838147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist.
    Yoshida Y; Naoe Y; Terauchi T; Ozaki F; Doko T; Takemura A; Tanaka T; Sorimachi K; Beuckmann CT; Suzuki M; Ueno T; Ozaki S; Yonaga M
    J Med Chem; 2015 Jun; 58(11):4648-64. PubMed ID: 25953512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Preclinical and clinical efficacy of orexin receptor antagonist Lemborexant (Dayvigo
    Koebisu M; Koyama N; Nishida M; Muramoto K
    Nihon Yakurigaku Zasshi; 2021; 156(2):114-119. PubMed ID: 33642529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia.
    Bonaventure P; Shelton J; Yun S; Nepomuceno D; Sutton S; Aluisio L; Fraser I; Lord B; Shoblock J; Welty N; Chaplan SR; Aguilar Z; Halter R; Ndifor A; Koudriakova T; Rizzolio M; Letavic M; Carruthers NI; Lovenberg T; Dugovic C
    J Pharmacol Exp Ther; 2015 Sep; 354(3):471-82. PubMed ID: 26177655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.
    Betschart C; Hintermann S; Behnke D; Cotesta S; Fendt M; Gee CE; Jacobson LH; Laue G; Ofner S; Chaudhari V; Badiger S; Pandit C; Wagner J; Hoyer D
    J Med Chem; 2013 Oct; 56(19):7590-607. PubMed ID: 23964859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist.
    Suzuki R; Nozawa D; Futamura A; Nishikawa-Shimono R; Abe M; Hattori N; Ohta H; Araki Y; Kambe D; Ohmichi M; Tokura S; Aoki T; Ohtake N; Kawamoto H
    Bioorg Med Chem; 2015 Mar; 23(6):1260-75. PubMed ID: 25693785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies.
    Fagan H; Jones E; Baldwin DS
    CNS Drugs; 2023 Jan; 37(1):1-12. PubMed ID: 36436175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate.
    Letavic MA; Bonaventure P; Carruthers NI; Dugovic C; Koudriakova T; Lord B; Lovenberg TW; Ly KS; Mani NS; Nepomuceno D; Pippel DJ; Rizzolio M; Shelton JE; Shah CR; Shireman BT; Young LK; Yun S
    J Med Chem; 2015 Jul; 58(14):5620-36. PubMed ID: 26087021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders.
    Pałasz A; Lapray D; Peyron C; Rojczyk-Gołębiewska E; Skowronek R; Markowski G; Czajkowska B; Krzystanek M; Wiaderkiewicz R
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):157-68. PubMed ID: 23702225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutics development for addiction: Orexin-1 receptor antagonists.
    Perrey DA; Zhang Y
    Brain Res; 2020 Mar; 1731():145922. PubMed ID: 30148984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review.
    Besterman AD; Jeste SS
    Eur Child Adolesc Psychiatry; 2023 Mar; 32(3):527-531. PubMed ID: 34611728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.